CVS Health plans to split into two publicly traded companies by the first half of 2028, according to CNBC. The separation would divide its pharmacy business, including roughly 9,000 retail locations, from its insurance business and its pharmacy benefit manager, Caremark.

CVS CEO David Joyner told CNBC's "Squawk on the Street" that in 2024 the company was "in a turnaround" without the flexibility, cash or performance to execute a split. He told analysts on a Wednesday call that the decision comes "out of strength."

Analysts say the economics have changed. Brian Tanquilut, senior equity research analyst at Jefferies, said that "back then, the idea of retail standing alone was unthinkable." Michael Cherny, senior research analyst at Leerink Partners, said the pharmacy business has shown stability. CNBC reports that CVS has posted eight consecutive quarters of beating Wall Street earnings estimates.

The company expects at least $15.5 billion in operating cash flow in 2026, up from $9.1 billion in 2024, according to the report. CNBC also reports that CVS shares fell about 12% after the announcement.

The retail pharmacy segment still runs low margins, at roughly 4% to 5%, according to the report. Analysts quoted by CNBC say it may now be stable enough to operate independently, though investors may value it at a discount. RBC Capital Markets analyst Ben Hendrix said that lower valuation has weighed on CVS's overall value.

Caremark faces state-level legal and regulatory scrutiny. Tennessee and Arkansas have passed laws that would bar one company from owning both a pharmacy and a PBM, though CNBC reports the Arkansas measure has been held up in court. Joyner told the Wall Street Journal that regulatory issues were not the reason for the split. CVS has said the separation follows a strategic review.